Creative Biolabs offers expert protein engineering and manufacturing to overcome native IL-21 limitations. We provide customized molecular design, creating proprietary IL-21 muteins with controlled potency and extended half-life via Fc or HSA fusion. We specialize in targeted delivery by producing immunocytokines that guide IL-21 activity to specific molecular targets, such as PD-1, ensuring localized immune activation. Backed by QbD-compliant biomanufacturing and in vitro validation, clients receive high-purity bulk protein and de-risked lead candidates with superior safety and efficacy for their immunotherapy programs.
IntroductionWhat We Can OfferTypes of Our ServicesWhy Creative BiolabsCustomer ReviewsFAQsRelated ServicesContact Us
Engineering IL-21 to Overcome Therapeutic Limitations
Interleukin-21 (IL-21) is a critical type I cytokine recognized as a potent immune agonist that enhances the proliferation and effector function of CD8+ T cells and NK cells. While native IL-21 has demonstrated promising anti-tumor activities, its therapeutic application is severely limited by a short serum half-life, requiring high and frequent dosing. Furthermore, preclinical data show that while IL-21 activates T cells, it also simultaneously induces the expression of inhibitory checkpoints (PD-1, Tim-3, Lag-3), creating a self-limiting therapeutic feedback loop.
Fig.1 IL21R was differentially expressed among tumor-infiltrating immune cells. 1
What We Can Offer
Customized Mutein Library Design
We provide tailored IL-21 mutein generation, focusing on engineering variants with precisely attenuated potency to maximize the therapeutic window and minimize off-target systemic toxicity. This ensures localized activation at the tumor site.
Rational Targeting Strategy Development
Full support in selecting and designing the optimal targeting moiety (e.g., anti-PD-1, anti-CD20, or novel TME markers) to create highly specific and functionally synergistic immunocytokines.
End-to-End PK/PD Optimization
Integrated in silico modeling and rigorous in vitro validation services to ensure your engineered IL-21 construct achieves the desired serum half-life, systemic safety, and robust local biological activity.
QbD-Driven Process Development
Efficient upstream and downstream process development leveraging quality-by-design (QbD) principles to ensure product consistency and robust manufacturing protocols from the outset.
Types of IL-21 Half-Life Extension & Targeted Delivery Engineering Services at Creative Biolabs
Anti-PD-1/IL-21 Fusion Protein Development Service
This service is centered on the bifunctional immunocytokine strategy. We fuse an IL-21 mutein to an anti-PD-1 antibody (or fragment) to create a single molecule that provides both checkpoint blockade and localized IL-21 activation. This is ideal for overcoming T cell exhaustion in PD-1-high TMEs and has been shown to deliver superior results to simple combination therapy.
Anti-CD20/IL-21 Immunocytokine Development Service
Tailored for hematological malignancies or solid tumors with CD20 expression (e.g., in B cells or TME-associated structures). This service targets the IL-21 payload to CD20-expressing cells, capitalizing on IL-21's role in B cell regulation while ensuring anti-tumor immunity in the surrounding microenvironment.
We don't just extend the half-life; we incorporate rationally designed IL-21 muteins to precisely control cytokine potency, ensuring that high T cell activation occurs primarily at the tumor site where the targeting moiety concentrates.
Dual-Action Immunocytokine Expertise
Our Anti-PD-1/IL-21 fusion technology allows for a two-in-one therapeutic that simultaneously blocks an immune checkpoint and delivers an activating signal, offering superior efficacy over simple combinations of two separate agents.
Optimized Pharmacokinetics
Utilizing proven Fc and HSA-binding domain fusion technologies, we guarantee superior serum half-life, which is essential for achieving sustained anti-tumor immunity in vivo.
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
Reduced Systemic Toxicity
Using Creative Biolabs' IL-21 mutein design in our research has significantly improved the therapeutic window for our IL-21-based combinatorial regimen by eliminating toxicity concerns seen with wild-type cytokine. Their functional validation data were crucial for lead selection. – J**e B**.
Functional Combination Efficacy
The Anti-PD-1/IL-21 immunocytokine is a powerful tool. It not only blocks the PD-1 pathway but also provides a localized IL-21 boost precisely where it's needed, circumventing the counter-regulatory Tim-3 upregulation that derailed our previous dual-agent approach. – Ali** K**
FAQs
Q:
Will the IL-21 mutein designs compromise the therapeutic efficacy of the cytokine?
A:
Not at all. Our mutein designs are rationally attenuated to reduce systemic activity and prevent off-target toxicity. When these muteins are delivered locally via the targeting antibody (e.g., to the PD-1+ T cell surface), the local concentration is high enough to drive robust STAT3 signaling and effector function, as demonstrated by preclinical studies.
Q:
How does the targeted IL-21 fusion compare to just combining a free anti-PD-1 antibody and free IL-21?
A:
Preclinical data shows that combining free agents often induces significant systemic toxicity and, critically, can trigger counter-regulatory mechanisms (Tim-3, Lag-3) that limit efficacy. Our single-molecule fusion solves both issues: it reduces systemic toxicity and ensures the activating IL-21 signal is delivered only after the inhibitory PD-1 signal is blocked, creating a more synergistic and localized effect.
Related Services
TCR/CAR Expression Analysis
To ensure the quality and efficacy of engineered cell therapies, this service provides a comprehensive analysis of T cell receptor (TCR) and chimeric antigen receptor (CAR) expression.
The generation of engineered fusion proteins significantly increases the risk of anti-drug antibody (ADA) formation, which can compromise clinical safety and efficacy.
Creative Biolabs' IL-21 half-life extension & targeted delivery engineering services are your premier solution for moving beyond traditional cytokine therapy. The platform furnishes rationally designed IL-21 muteins and multi-functional immunocytokines, substantiated by robust preclinical evidence, to achieve superior pharmacokinetics (PK), mitigated toxicity, and enhanced T cell function for immunotherapy programs. Contact our team for more information and to discuss your project.
Reference
Wu, Shaoxian et al. "The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy." Frontiers in cell and developmental biology vol. 9 779865. 15 Nov. 2021. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2021.779865
Fig.1 IL21R was differentially expressed among tumor-infiltrating immune cells. 1
